Clinical trials: Pancreatic Metastasis
Pancreatic Cancer
Retlirafusp Alfa Plus Apatinib and Chemotherapy as Second-Line Treatment for Pancreatic Cancer
This is a prospective, open-label, single-arm clinical study designed to evaluate the efficacy and safety of retlirafusp alfa combined with apatinib and chemotherapy as second-line treatment in patients with unresectable locally…
- Trial name
- NCT07773363
- Testing
- Retlirafusp Alfa, Apatinib, Fluoropyrimidine-Based Chemotherapy
- Volunteers
- 37 people
- Sponsor
- Tang-Du Hospital
Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer
MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
Brain metastases are the most common intracranial malignancy occurring in 20-40% of all cancers, and the presence of CNS metastases is associated with a poor prognosis.
- Conditions
- Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer, Breast Cancer, Cancer of Breast
- Trial name
- NCT02669914
- Testing
- MEDI4736
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Washington University School of Medicine
Pancreatic Ductal Adenocarcinoma, Locally Advanced Cancer
OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDAC
TEDOPAM is a randomized (1.1.1) non-comparative phase II study. This study will assess the efficacy and safety of OSE2101 alone or in combination with nivolumab followed by FOLFIRI reintroduction, versus FOLFIRI as maintenance…
- Conditions
- Pancreatic Ductal Adenocarcinoma, Locally Advanced Cancer, Metastatic Cancer
- Trial name
- TEDOPAM (NCT03806309)
- Testing
- FOLFIRI, OSE2101
- Where
- 28 sites in France
- Volunteers
- 106 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Pancreatic Cancer
Evaluating Nimotuzumab in Combination With AG Regimen for Pancreatic Cancer With Liver Metastases : A Prospective, Single-Arm, Phase II Study
Patients with PCLM account for the majority of our department's pancreatic cancer cases and often have limited surgical options due to the aggressive nature of their tumors.
- Trial name
- NCT06404840
- Testing
- nimotuzumab, AG chemotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Pancreatic Ductal Adenocarcinoma (PDAC)
OSCAR I STUDY - The ONCObind CTC Removal Study
This study is a Prospective Single Arm Open Label Feasibility trial to evaluate the initial safety and signal of efficacy of a novel extracorporeal blood purification (EBP) procedure in metastatic PDAC refractory to systemic…
- Trial name
- NCT06481397
- Testing
- ONCObind (Onco-Seraph) 100 Filter
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- ExThera Medical Corporation
Pancreatic Cancer, Breast Cancer
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
Study of NGM831 as Monotherapy and in Combination with Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
- Conditions
- Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT05215574
- Testing
- NGM831, NGM831 plus pembrolizumab (KEYTRUDA®), NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)
- Where
- 9 sites in United States
- Volunteers
- 130 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Breast Cancer, Colorectal Cancer
Phase I Study of CDX-1307, hCG-B Vaccine, for Patients With Incurable, Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, Bladder or Ovarian Cancer
This research study is for individuals who have advanced breast, colon, pancreatic, ovarian or bladder cancer. Celldex Therapeutics, Inc.
- Conditions
- Breast Cancer, Colorectal Cancer, Pancreatic Cancer, Bladder Cancer
- Trial name
- CDX1307-02 (NCT00648102)
- Testing
- CDX-1307
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Celldex Therapeutics
Metastatic Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8
CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer
This phase I trial tests the safety, side effects, and best dose of emavusertib (CA-4948) in combination with gemcitabine and nab-paclitaxel in treating patients with pancreatic ductal adenocarcinoma that has spread from where it…
- Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT05685602
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 26 sites in United States
- Volunteers
- 43 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer
A Study With LY293111, Gemcitabine and Placebo in Patients With Pancreatic Cancer
The purpose of this study is to determine the effectiveness and side effects of LY293111 given in combination with gemcitabine in patients with pancreatic cancer.
- Trial name
- NCT00055250
- Testing
- Gemcitabine, LY293111
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- Eli Lilly and Company
Advanced Pancreatic Cancer
Ntraperitoneal Thermal Perfusion Combined With Chemotherapy Versus Chemotherapy
In view of the existence of malignant ascites in patients with advanced pancreatic cancer, we put forward the heat abdominal cavity perfusion chemotherapy combined albumin paclitaxel and gemcitabine compared with albumin…
- Trial name
- NCT04707118
- Testing
- cisplatin+Nab-paclitaxel+GEM, Nab-paclitaxel+GEM
- Where
- China
- Volunteers
- 106 people
- Sponsor
- Fudan University
Pancreatic Ductal Adenocarcinoma
Nab-Paclitaxel + Cisplatin + Gemcitabine in Untreated Metastatic Pancreatic Adenocarcinoma
This is a phase II open-label study evaluating the efficacy and safety of nab-paclitaxel cisplatin, and gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma.
- Trial name
- NCT03915444
- Testing
- NabCG (nab-Paclitaxel + Cisplatin + Gemcitabine)
- Where
- 4 sites in United States
- Volunteers
- 42 people
- Sponsor
- HonorHealth Research Institute
Brain and Central Nervous System Tumors, Gastrointestinal Carcinoid Tumor
Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors
RATIONALE: Radiolabeled octreotide can locate tumor cells and deliver radioactive tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Neuroblastoma
- Trial name
- NCT00049023
- Testing
- 90Y-DOTA-tyr3-OCTREOTIDE
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- O'Dorisio, M S
Carcinoma, Non Small Cell Lung, Carcinoma, Pancreatic Ductal
A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies
The purpose of this study is to learn about the safety and the effects of PF-08046037 alone or with sasanlimab for the treatment of certain advanced or metastatic malignancies.
- Conditions
- Carcinoma, Non Small Cell Lung, Carcinoma, Pancreatic Ductal, Malignant Melanoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Trial name
- NCT06974734
- Testing
- PF-08046037, sasanlimab
- Where
- 15 sites in United States, Puerto Rico
- Volunteers
- 8 people
- Sponsor
- Pfizer
Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer
This phase II trial studies how well niraparib and dostarlimab work in treating patients with germline or somatic BRCA1/2 and PALB2 mutated pancreatic cancer that has spread to other places in the body (metastatic).
- Trial name
- NCT04493060
- Testing
- Dostarlimab, Niraparib
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Mayo Clinic
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
This clinical trial is studying the amount of EF5 and motexafin lutetium present in tumor cells and/or normal tissues of patients with abdominal (such as ovarian, colon, or stomach cancer) or non-small cell lung cancer.
- Conditions
- Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Fallopian Tube Cancer, Gastrointestinal Stromal Tumor
- Trial name
- NCT00087191
- Testing
- EF5, motexafin lutetium, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Adenocarcinoma Pancreas
Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Patients With Peritoneal Metastasis From Pancreatic Adenocarcinoma
Palliative systemic therapy is the standard treatment option for patients with pancreatic ductal adenocarcinoma (PDAC) and peritoneal metastasis (PM), who have a median overall survival of only 6-11 months and a serious adverse…
- Trial name
- NCT07253662
- Testing
- PIPAC, Nab-paclitaxel
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Northwell Health
Metastatic Pancreatic Carcinoma
HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients
This study is a single-arm phase II clinical study to include 32 patients with advanced pancreatic cancer with KRAS G12D mutation to evaluate the effectiveness of HRS-4642 combined with nitutuzumab and AG for first-line treatment…
- Trial name
- NCT06770452
- Testing
- HRS-4642, Nimotuzumab, gemcitabine + nab-paclitaxel
- Where
- 2 sites in China
- Volunteers
- 133 people
- Sponsor
- Zhejiang University
Pain, Pancreatic Cancer
Standard Pain Control or Intrathecal Therapy in Controlling Pain in Patients With Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer
RATIONALE: Giving medications in different ways may change their effectiveness in controlling pain. It is not yet known whether intrathecal therapy is more effective than standard therapy in controlling pain in patients with…
- Trial name
- NCT00660348
- Testing
- morphine sulfate, Medtronic intrathecal pump
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pancreatic Neuroendocrine Tumour Metastatic
A Biological Prospective Study in Patients With Metastatic Pancreatic NETs Treated With Everolimus
Everolimus represents an approved therapy for patients with advanced well/moderately differentiated pancreatic NETs. Although some patients could benefit from this drug in terms of long-term tumor growth control, others are…
- Trial name
- NCT02305810
- Testing
- Everolimus 10 mg daily
- Where
- Italy
- Volunteers
- 54 people
- Sponsor
- European Institute of Oncology
Circulating Tumor Cells, Pancreatic Adenocarcinoma
Detection of Circulating Tumor Cells for the Diagnostic of Pancreatic Adenocarcinoma.
Histological proof is a crucial and necessary step for appropriate care in oncology. In the case of pancreatic cancer, histological proof from pathological analysis of the surgical specimen is very rare due to the limited number…
- Conditions
- Circulating Tumor Cells, Pancreatic Adenocarcinoma, Circulating Tumor DNA (KRAS), CA 19.9
- Trial name
- CTC-Pancreas (NCT02072616)
- Testing
- Pancreatic adenocarcinoma diagnosis
- Where
- France
- Volunteers
- 101 people
- Sponsor
- University Hospital, Rouen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.